

Docket No. 283361US0PCT

10/562659
IAP5 Rec'd PCT/PTO 29 DEC 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Catherine MENIER, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/FR04/01663

GAU:

FILED: Herewith

EXAMINER:

FOR: USE OF COMPOSITIONS COMPRISING A SOLUBLE FORM OF HLA-G IN THE TREATMENT OF BLOOD DISEASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 283361US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/FR04/01663	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Catherine MENIER, et al.		10/562659	
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	6 511 807	01/28/03	ROTHENBERG Barry E.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	0 677 582	10/18/95	EP		NO	
	AP	96/17085	06/06/96	WO		NO	
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	LE DISCORDE, M. et al., "HLA-G: Immunotolerance in normal and pathological physiology", Pathologie Biologie, Vol. 50, No.1, PP.45-51, 2002, with English abstract.					
	AX	GERAGHTY D.E., "Production of Monoclonal Antibodies Specific for the New Class 1 Antigen HLA-G and their use to examine expression in Trophoblast Cells" FASEB Journal, FED, of American Soc. for Experimental Biology Vol., 4 No. 7, Page A2216, 1990					
	AY	MENIER C. et al., "Nonclassical HLA-G5 class I soluble molecule is present in the erythropoietic lineage from early embryo through to adulthood: Potential role in erythroblast differentiation and in angiogenesis.", Tissue Antigens, Vol.62, No.4, page 341, 2003					
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							